Should persons with acute myeloid leukemia have a transplant in first remission

Leukemia

Volumn 28, Issue 10, 2014, Pages 1949-1952

  Gale, R P ^a   Wiernik, P H ^b   Lazarus, H M ^c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b Cancer Research Foundation of New York   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE MYELOBLASTIC LEUKEMIA; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONSOLIDATION CHEMOTHERAPY; GRAFT RECIPIENT; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; LEUKEMIA CELL; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LONG TERM SURVIVAL; MINIMAL RESIDUAL DISEASE; MYELOBLAST; PRIORITY JOURNAL; RECURRENCE RISK; REMISSION; REVIEW; SURVIVAL TIME; ALLOTRANSPLANTATION; CHEMISTRY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMIA, MYELOID, ACUTE; PROCEDURES; RECURRENT DISEASE; TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; NEOPLASM, RESIDUAL; RECURRENCE; REMISSION INDUCTION; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84921779422     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.129     Document Type: Review

References (29)

1. Koreth J, Schlenk R, Kopecy KJ, Honda S, Sierra J, Djulbegovic BJ et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first remission: systematic review and meta-analysis of prospective clinical trials. J Am Med Ass 2009; 301: 2349-2361
2. Gale RP, Eapen M, Logan B, Zhang MJ, Lazarus H. Comparing therapy-options: are there roles for observational databases and structured quantification of expert opinion to answer therapy controversies in transplants? Bone Marrow Transplant 2009; 43: 435-446
3. Cornell JE, Mulrow CD, Localio R, Stack CB, Meibohm AR, Guallar E. Randomeffects meta-analysis of inconsistent effects: a time for change. Ann Intern Med 2014; 160: 267-270
4. Schlenk RF, Dö hner K, Krauter J, Frö hling S, Corbacioglu A, Bullinger L et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1909-1918
5. Gale RE, Hills R, Kottaridis PD, Srirangan S, Wheatley K, Burnett AK et al. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia from the UK MRC AML10 and 12 trials. Blood 2005; 106: 3658-3665
6. Forman SJ, Rowe JM. The myth of the second remission of acute leukemia in the adult. Blood 2013; 121: 1077-1082
7. Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010; 363: 2091-2101
8. Agency for Healthcare Research and Quality, 2010 National Healthcare Disparities Report. US Department of Health and Human Services. Agency for Healthcare Research and Quality: Rockville, MD, 2011
9. Burnett AK, Goldstone A, Hills RK, Milligan D, Prentice A, Yin J et al. Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. J Clin Oncol 2013; 31: 1293-1301
10. Hernan MA, Hernandez-Diaz S, Robins JM. Randomized trials analyzed as observational studies. Ann Intern Med 2013; 159: 560-562
11. Labopin M, Gorin NC, Polge E, Socié G, Gurman G, Gluckman E et al. A prospective registration study to determine feasibility of hematopoietic SCT in adults with acute leukemia: planning, expectations and reality. Bone Marrow Transplant 2014; 49: 376-381
12. Schlenk RF, Benner A, Krauter J, Bü chner T, Sauerland C, Ehninger G et al. Individual patient data-based meta-analysis of patients aged 16-60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 2004; 22: 3741-3750
13. Marcucci G, Mró zek K, Ruppert AS, Maharry K, Kolitz JE, Moore JO et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol 2005; 23: 5705-5717
14. Schlenk RF, Taskesen E, van Norden Y, Krauter J, Ganser A, Bullinger L et al. The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. Blood 2013; 122: 1576-1582
15. Breems DA, Van Putten WL, Hujigens PC, Ossenkoppele GJ, Verhoef GE, Verdonck LF et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 2005; 23: 1969-1978
16. Chevallier P, Labopin M, Turlure P, Prebet T, Pigneux A, Hunault M et al. A new leukemia prognostic scoring system for refractory/relapsed adult acute myelogenous leukaemia patients: a GOELAMS study. Leukemia 2011; 25: 939-944
17. Luger SM, Ringdén O, Zhang MJ, Pérez WS, Bishop MR, Bornhauser M et al. Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant 2012; 47: 203-211
18. Walter RB, Othus M, Borthakur G, Ravandi F, Cortes JE, Pierce SA et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol 2011; 29: 4417-4423
19. Leening MJ, Vedder MM, Witteman JC, Pencian MJ, Steyerberg EW. Net reclassification improvement: computation, interpretation and controversies: a literature review and clinician's guide. Ann Intern Med 2014; 160: 122-131
20. Goldman JM, Gale RP. What does MRD in leukemia really mean? Leukemia 2014; 28: 1131
21. Terwijn M, van Putten WL, Kelder A, van der Velden VH, Brooimans RA, Pabst T et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A Study. J Clin Oncol 2013; 31: 3889-3897
22. Butturini A, Klein J, Gale RP. Modeling minimal residual disease (MRD) testing. Leuk Res 2002; 27: 293-300
23. Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS et al. Clonal evolution in relapsed acute myeloid leukemia revealed by whole-genome sequencing. Nature 2012; 481: 506-510
24. Gale RP, Goldman JM. Treating chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Acta Haematol 2013; 213: 192-195
25. Marin D. Patient with chronic myeloid leukemia in complete cytogenetic response: what does it mean, and what does one do next. J Clin Oncol 2013; 52: 9230
26. Gale RP, Park RE, Dubois R, Bitran JD, Buzdar A, Hortobagyi G et al. Delphiconsensus panel analysis of appropriateness of high-dose chemotherapy and blood cell or bone marrow autotransplants in women with breast cancer. Clin Transplant 2000; 14: 32-41
27. Ritchie DS, Neeson PJ, Khot A, Peinert S, Tai T, Tainton K et al. Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther 2013; 21: 2122-2129
28. Pagel JM, Gooley TA, Rajendran J, Fisher DR, Wilson WA, Sandmaier BM et al. Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood 2009; 114: 5444-5453
29. Goodyear OC, Dennis M, Jilani NY, Loke J, Siddique S, Ryan G et al. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood 2012; 119: 3361-3369.